Regarding the pharmacology of opioid analgesics used in acute pain management, all of the following statements are correct EXCEPT:

Explanation

## Opioid Pharmacology in Acute Pain Management ### Key Metabolic and Pharmacokinetic Profiles **Key Point:** Tramadol is a unique analgesic with DUAL mechanisms of action — it is NOT a pure mu-opioid agonist. | Opioid | Primary Mechanism | Secondary Mechanism | Clinical Implication | |--------|-------------------|-------------------|----------------------| | Morphine | Mu-opioid agonist | Glucuronidation produces active M6G metabolite | Accumulation risk in renal failure | | Fentanyl | Mu-opioid agonist (high potency) | High lipophilicity → rapid CNS entry | Faster onset, shorter duration than morphine | | Tramadol | Weak mu-opioid agonist | Norepinephrine & serotonin reuptake inhibition | Multimodal analgesia; lower abuse potential | | Remifentanil | Mu-opioid agonist (ultra-potent) | Ester hydrolysis by plasma/tissue esterases | Context-sensitive half-life independent of infusion duration | ### Why Each Statement Matters **Option 1 (Morphine metabolism):** ✓ CORRECT Morphine-6-glucuronide (M6G) is the active analgesic metabolite; morphine-3-glucuronide is inactive. Both accumulate in renal impairment. **Option 2 (Fentanyl kinetics):** ✓ CORRECT Fentanyl's lipophilicity (log P ~4) allows rapid blood–brain barrier crossing, explaining its faster onset (5–10 min IV) and shorter duration (30–60 min) versus morphine (onset 10–20 min, duration 3–4 hours). **Option 3 (Tramadol mechanism):** ✗ INCORRECT Tramadol is a **weak mu-opioid agonist** AND inhibits reuptake of norepinephrine and serotonin. This dual mechanism provides multimodal analgesia and reduces opioid-related side effects. Stating it acts "solely" as a mu-opioid agonist is factually wrong. **Option 4 (Remifentanil metabolism):** ✓ CORRECT Remifentanil is hydrolyzed by nonspecific plasma and tissue esterases, resulting in a context-sensitive half-life of ~3–10 minutes regardless of infusion duration — ideal for short procedures and rapid offset. **High-Yield:** Tramadol's nonopioid mechanisms (norepinephrine and serotonin reuptake inhibition) explain why it has a lower abuse potential and can be used in opioid-tolerant patients without full cross-tolerance. **Clinical Pearl:** The distinction between tramadol and pure mu-opioids is clinically important — tramadol does NOT produce respiratory depression to the same degree and has a lower risk of physical dependence, making it a bridge analgesic in many pain management protocols. [cite:KD Tripathi 8e Ch 12]